Has Geraldo Saavedra, MD received payments from drug or device companies?

Yes. Drug and device makers reported $698,116 in general payments to Geraldo Saavedra, MD across 3,125 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Geraldo Saavedra, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Geraldo Saavedra, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Geraldo Saavedra, MD

Endocrinology, Diabetes & Metabolism · Whitehall, PANPI 1700861630

Payments from drug & device makers

$698,116in general payments, 2019–2025

Across 3,125 payments — averaging $223.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$366K
Novo Nordisk$129K
Boehringer Ingelheim$39K
Sanofi-aventis U.S. LLC$33K
Insulet Corporation$28K
AstraZeneca$22K
plus $81K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	802	$365,570
Novo Nordisk	311	$129,003
Boehringer Ingelheim	138	$39,225
Sanofi-aventis U.S. LLC	97	$32,817
Insulet Corporation	51	$28,184
AstraZeneca(2 entities)	147	$21,965
Mannkind Corporation	144	$17,460
Esperion Therapeutics, Inc.	78	$14,734
Cequr Corporation	11	$7,832
AbbVie(2 entities)	100	$5,427
Amgen(2 entities)	159	$4,842
Medtronic(2 entities)	41	$4,790
Corcept Therapeutics	85	$2,214
Xeris Pharmaceuticals, Inc.	119	$2,197
Tandem Diabetes Care, Inc.	8	$2,188
Bayer	49	$1,914
Abbott	69	$1,715
OPKO Pharmaceuticals, LLC	179	$1,654
Radius Health, Inc.	60	$1,227
Johnson & Johnson	20	$1,177
Amarin Pharma, Inc.	85	$1,120
Madrigal Pharmaceuticals	14	$852
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	46	$833
Eli Lilly	2	$721
Novartis	39	$667
Antares Pharma, Inc.	33	$655
Dexcom, Inc.	7	$560
Vifor Pharma, Inc.	18	$528
Merck	36	$514
Senseonics, Incorporated	5	$438
Recordati_rare_diseases_inc.	15	$432
BETA Bionics, Inc.	5	$365
Astellas Pharma US Inc	13	$277
Kyowa Kirin, Inc.	8	$270
Sunovion Pharmaceuticals Inc.	2	$236
Averitas Pharma Inc.	6	$202
Pfizer	9	$196
Ipsen Biopharmaceuticals, Inc	8	$188
Biohaven Pharmaceutical Holding Company Ltd.	2	$187
Shire North American Group Inc	4	$180
Aimmune Therapeutics, Inc.	3	$167
Takeda Pharmaceuticals U.S.A., Inc.	8	$160
Tolmar, Inc.	9	$160
Nestle Healthcare Nutrition Inc.	2	$142
Sequel Med Tech, LLC	3	$140
Biohaven Pharmaceuticals, Inc.	2	$140
BD	7	$138
Gilead	2	$127
Kowa Pharmaceuticals America, Inc.	9	$114
Amryt Pharma Holdings Ltd	2	$113
Valeritas, Inc.	3	$112
Avanir Pharmaceuticals, Inc.	1	$100
Halozyme Inc	5	$94
Amphastar Pharmaceuticals, Inc.	5	$90
Zealand Pharma US, Inc.	5	$84
GSK	1	$83
Companion Medical, Inc.	6	$70
Eisai Inc.	1	$70
Currax Pharmaceuticals LLC	4	$58
Ascendis Pharma Endocrinology Inc	2	$51

How this compares

$698,116 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$30,727

Medicare patients

119

Services billed

377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Whitehall

Mona Al MukaddamPhiladelphia$3.9M
Serge JabbourPhiladelphia$3.1M
Mihaela BiscoveanuPhiladelphia$1.5M
Barbara SimonPhiladelphia$1M
Mitchell LazarPhiladelphia$1M
Vijay BahlPittsburgh$998K
Intekhab AhmedPhiladelphia$926K
Erin KershawPittsburgh$804K
Arvind CavaleFeasterville Trevose$662K
Jane MayrinPhiladelphia$628K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →